|
Renowned as the “Pharmacy of the world”, the booming pharmaceutical industry of India, has made impressive strides in the last two decades.
Indian dominance in this sector is evident from the fact that it is the largest provider of generic drugs globally. It meets more than half of global demand for vaccines, 40 per cent of generic demand in the United States, and 25 per cent of total medicine demand in the United Kingdom.
Moreover, it is a leader in path-breaking innovation especially when it comes to providing life-saving medicines at affordable prices to countries that need them the most.
Behind India’s pharma success story is the world class manufacturing excellence, robust infrastructure, cost-competitiveness, trained human capital and innovation. India has a large pool of trained pharmaceutical professionals which enables industry to develop generic drugs at significantly lower prices
With a strong network of 3,000 pharmaceutical companies and approximately 10,500 manufacturing units spread across the country, India has a distinct competitive advantage in the global pharmaceutical industry.
Globally, India ranks third in terms of pharmaceutical production by volume and 14th by value and supplying medicines to over 200 countries in the world. India’s pharma sector, which is currently valued at around US$ 50 billion, is expected to touch US$ 130 billion the by the year 2030. By 2047 the pharma industry is expected to reach a figure of US$ 500 billion and poised to be the number one manufacturer in the world.
CPHI & P-MEC India event
Giving a further push to the fast-growing pharma sector of India, CPHI & P-MEC India, South Asia’s biggest pharma event, will be unfolding from November 29 to December 1, 2022 at the India Expo Centre, Greater Noida, Delhi – NCR.
Embracing modernization, the 16th CPHI & P-MEC India creates platforms to showcase modern technologies critical in facilitating advancement in India’s pharma machinery, technology, and ingredients industries.
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees. To stimulate the anticipated growth of the industry, a pre-connect congress will take place on November 28 at Crowne Plaza, Mayur Vihar, New Delhi.
The expo will yet again be a marketplace to bridge the ecosystem with knowledge, technologies, and market opportunities. CPHI & P-MEC India are expected to witness over 1500 exhibitors, more than 40,000 executives and representation from over 80 countries, of which nearly 50 per cent are C-Suite and 65 per cent have purchasing responsibility.
It gives direct access highly targeted senior pharma executives, buyers, procurement managers, contract manufacturers, hospital administration, and many more along with national and state regulatory boards, and policymakers to congregate and conduct business, arrive at solution-driven innovations to counteract economic uncertainties and domestic trade in India.
CPHI and P-MEC India is a gateway to discover various opportunities and build successful business relationships with hundreds of participating companies and industry leaders.
Some of the key exhibitors include Hetero, Aurobindo, Signet, Teva, Optimus, Lonza Capsules, Merck, IMCD, Fette Compacting, Elmach, ACG, BD Pharma, IMA, Cadmach, GEA and many more. This year again the expo garnered extensive support from associations like Pharmexcil, CIPI, IDMA, ASPA, IPA, IPEC, and KDPMA reaffirming it as industry’s most promising show.
Talking on this year’s CPHI & P-MEC India Expo, Yogesh Mudras, Managing Director, Informa Markets in India said, “The Indian pharma market is rising at an annual growth rate of 15 per cent, which is twice the world market growth rate. To further accelerate the growth of this industry, the government has approved incentives to the tune of almost Rs 22,000 crores and 100 per cent FDI, under the automatic route for greenfield pharmaceuticals.
Over the last 15 years, our show CPHI and P-MEC India has demonstrated excellence in supporting the industry and growing along with it by curating highly effective platforms for showcasing technology solutions, knowledge sharing, networking, and advocacy in the past and will continue to act as a catalyst to ‘Make in India ‘movement and provide an impetus to Indian economy. The expo will surely provide a huge platform to establish and enhance business by meeting active suppliers looking for collaboration with the Indian Pharma and Healthcare market. Every edition of CPHI and P-MEC India has set a successful milestone for its esteemed visitors and this year too, we will raise the bar to give a significant boost to this industry.”
The India Pharma Week, of which the expo is a prominent part, fill further provide and encourage the halo around the pharma sector. The marquee show starts with the pre-connect Congress that
will include Amit Saluja, Senior Director and Center Head - Gandhinagar CoE NASSCOM, Gandhinagar, Dr. Sanjit
Singh Lamba, CEO, Biocuris, Suresh Pattathil, President – OPPI & Managing Director and General Manager, Allergan India, and Vikram Srivastava, Head, Global Supply chain, Sun Pharmaceutical Industries Ltd amongst others.
The key topics of the panel discussions would include ‘Disrupting the pharmaceutical industry in the age of rapid technological growth’, ‘Paving the pathway for innovation in pharma R&D’,’ Adaptive, responsive, and flexible supply chain to fuel pharma growth’ and ‘Changing global dynamics & opportunities for enhancing India’s pharma exports.’
Alongside the display of the latest technologies, of CPHI & P-MEC India, the India Pharma Week which will include 9th Annual India pharma awards and CEO Roundtable on Day 1 will bring all key stakeholders in the pharmaceutical industry on a single platform to discuss, deliberate, and shares their thoughts on achieving the next phase of growth in pharma. Day 2 will see Women in Pharma Roundtable which an initiative is aimed at acknowledging and celebrating the significant and continued contribution of women to the pharmaceutical industry in a closed-door roundtable discussion.
Increased partnering
Talking about the significance of the event for the pharma sector in India, the organizers said it will be hugely important as partnering events are back in full swing after the pandemic and as India’s pharma industry expects a tremendous growth in 2023, forging partnerships and building business relationships will be more important than ever before. As one of the first in-person events in Asia will also help further build up regional partnerships in the aera.
One of the benefits of working from home that globally companies are realising, is the option of 365 partnering. CPHI India is offering online partnering platform which will remain open before and after the in- person event. So, the attendance will span pre, during and post so attendees and participants can pre-select meetings and catch up afterwards with potential partners and business contacts, they pointed out.
PMEC remains a huge part of the show as India is one of the target manufacturing hubs in the world and continues to modernise equipment from single use in biologics to continuous processing in solid dose forms and even API and it is exciting time as manufacturing looks to reduce cost – to develop and even innovate new manufacturing approaches, they added.
Pharmaceutical machinery is predicted to be in high demand as both generic companies and CDMOs invest in next generation equipment like continuous processing and advanced analytical equipment to help maintain the country’s impressive 15 per cent annualised growth rate.
Describing the current pharma scene of India, they said in the recently concluded CPHI Frankfurt, the CPHI Annual Survey findings show for the first time that Indian API manufacturing has surpassed the quality scores of even Europe’s leading API hub – Italy. Indian companies also reported surging interest from the EU and in particular USA. Companies in both the USA and Europe are reportedly deepening ties with India’s pharma industry as a response to recent macro-sourcing changes.
In fact, India has seen record rises in many categories and has overtaken Japan, Switzerland, Italy and France in the overall rankings, finishing only behind the UK, Germany and the US. The country was also identified by nearly 50 per cent of pharma industry executives as the biggest beneficiary of ‘geo-sourcing strategies’ in next three years. India recorded its largest ever improvements in scores for the quality of its ‘finished dose manufacturing’ and ‘API manufacturing’ – with a massive 15 per cent gain in the latter category.
“We are at a key moment for India as it achieves comparable and even improved quality with many European nations. This coupled with geo-sourcing strategies underway means that in the next year and the year’s that follow India is likely to see a sustained period as one of pharma’s fastest innovating and growing nations. What’s exciting for CPHI is that we are playing an integral role at the heart of this dynamism by empowering the country’s industry with the partnering it needs to fuel growth,” commented Olga Ponomareva-Stepnaya, brand manager for CPHI India.
|